Canadian Respiratory Journal / 2019 / Article / Tab 2

Research Article

Prognostic Value of Concomitant Bronchiectasis in Newly Diagnosed Diffuse Panbronchiolitis Patients on a Maintenance Therapy with Macrolides

Table 2

Medications, therapeutic effects, and exacerbation frequencies in DPB subjects with and without bronchiectasis during follow-up.

Treatment and outcomeWhole group ()DPB with Bronchiectasis ()DPB without Bronchiectasis () value

Macrolide antibiotics0.572
 Azithromycin179 (82.5)104 (80.6)75 (85.2)
 Clarithromycin23 (10.6)15 (11.6)8 (9.1)
 Erythromycin12 (5.5)7 (5.4)5 (5.7)
 Roxithromycin3 (1.4)3 (2.3)0 (0)
Regular ICS + LABA35 (16.1)18 (14.0)17 (19.3)0.291
Regular LAMA28 (12.9)18 (14.0)10 (11.4)0.576
Follow-up period (months)32.0 (18.5, 41.0)35.5 (16.0, 45.0)29.0 (21.0, 39.0)0.192
Exacerbation frequency (time/year)0.5 (0, 1.5)0.7 (0, 1.6)0.3 (0, 1.3)0.048
Treatment efficacy<0.001
 Healed36 (16.6)18 (20.5)18 (14.0)
 Improved102 (47.0)53 (60.2)49 (38.0)
 Unchanged39 (18.0)6 (6.8)33 (25.6)
 Deteriorating32 (14.7)7 (8.0)25 (19.4)
 Recurrent8 (3.7)4 (4.5)4 (3.1)
Overall response<0.001
 Responsive138 (63.6)67 (51.9)71 (80.7)
 Unresponsive79 (36.4)62 (48.1)17 (19.3)

Data are presented as median (interquartile range) or numbers (percentages). DPB: diffuse panbronchiolitis; ICS: inhaled corticosteroid; LABA: long-acting bronchial agonist; LAMA: long-acting muscarinic antagonist. Comparison of DPB subjects with and without bronchiectasis. The exacerbation frequency (time/year) was defined as the number of exacerbation events/duration of follow-up (months) × 12.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.